Study links popular GLP-1 weight-loss drugs to rare brain disorder
Researchers found a possible association between GLP-1 medications and Wernicke encephalopathy, a rare but serious neurological condition.
A large-scale study examined 195,979 cases and uncovered fifteen cases of Wernicke encephalopathy, a rare brain disorder caused by severe vitamin B1 deficiency. The condition appeared more frequently among users of GLP-1 medications than among users of other drugs. Most of the identified cases involved semaglutide, marketed as Ozempic, Wegovy and Rybelsus, or tirzepatide, sold as Mounjaro and Zepbound.
A majority of patients exhibited gastrointestinal problems such as weight loss, vomiting, loss of appetite or malnutrition, which can precipitate thiamine deficiency. Only two patients displayed the classic triad of altered mental state, gait disturbance and eye-movement abnormalities, highlighting diagnostic challenges. Researchers recommend that healthcare providers remain vigilant for Wernicke encephalopathy in patients taking these GLP-1 agents to prevent irreversible brain damage.
Why it matters
The findings warn doctors to watch for a treatable but potentially fatal brain disorder in users of widely prescribed weight-loss drugs.
In this story
